EXICURE (XCUR) Company Report

Exicure, Inc. announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma.
In the trial, 89.5% of participants (17 of 19) achieved the primary endpoint of collecting ≥2 × 10⁶ CD34+ cells/kg within two leukapheresis sessions.
Burixafor, administered in combination, was well tolerated and demonstrated an excellent safety profile, with no burixafor-related adverse events higher than Grade 2.
Notably, 87.5% of participants (14 of 16) who had prior exposure to daratumumab, a therapy associated with reduced mobilization, still achieved the primary endpoint.
Burixafor exhibits differentiated and rapid mobilization kinetics, allowing for peak peripheral levels of CD34+ cells within one hour of administration and same-day apheresis.

Dec 8, 2025, 9:30 PM

Exicure, Inc. Reports Q3 2025 Financial Results and Going Concern Warning

XCUR

Earnings

Profit Warning

M&A

Exicure, Inc. reported a net loss of $2.4 million for the third quarter of 2025, compared to a net loss of $1.1 million for the same period in 2024, primarily due to increased operating expenses following the acquisition of GPCR USA.
The company's cash and cash equivalents stood at $4.4 million as of September 30, 2025, a decrease from $12.5 million as of December 31, 2024.
Management stated that the existing cash and cash equivalents are not sufficient to continue funding operations, and substantial additional financing is needed in the short term.
Research and development expenses increased to $0.9 million in Q3 2025 from $0 in Q3 2024, and general and administrative expenses rose to $1.5 million from $1.4 million, both primarily due to the GPCR USA acquisition.

Nov 7, 2025, 9:07 PM

Get instant answers from SEC filings, earnings calls & more

EXICURE (XCUR)